Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$55.5KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Hing C. Wong
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 35
- Beta
- 2.27
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -7.29
Financials
Revenue
$55.5K-98.6%Net Income
$-3.22MEBITDA
$-2.96MFree Cash Flow
$-2.62MEPS (diluted)
$-2.83Shares Outstanding (diluted)
2.10M-55.9%Operating Expenses
$2.61MCash & Debt
$955.5KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $54.2K | $-7.96M | $-63.78 |
| 2024 | $2.57M | $-30.02M | $-185.75 |
| 2023 | $2.84M | $-24.99M | $-166.96 |
| 2022 | $6.72M | $-14.90M | $-99.83 |
| 2021 | $0.00 | $-12.86M | $-2.16 |
| 2020 | $4.10M | $-5.78M | $-0.96 |
| 2019 | $0.00 | $-7.29M | $-1.26 |
Valuation
HCWBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+11.11%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·6d ago·Neutral
…Clinical Development Highlights and Financial Results MIRAMAR, Fla., Nov. 16, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three and nine months ended September 30, 2026.
View source ↗ - Newsglobenewswire.com·16d ago·Neutral
HCW Biologics' Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer Designated as one of the Top 150 abstracts submitted for the 41 st Annual Meeting of the Society for Immunotherapy of Cancer
View source ↗ - Newsglobenewswire.com·16d ago·Neutral
…or infiltration while mitigating immunosuppression MIRAMAR, Fla., Nov. 06, 2026 (GLOBE NEWSWIRE) -- -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company and leading developer in novel multi-functional fusion immunotherapeutics, for the treatment of autoimmune diseases, cancer, and senescence-associated dysplasia, announced a major update for its multivalent, second-generation T-Cell Engager (“TCE”) Program, presented at th…
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing Provides funding needed to complete HCW9302 Phase 1 study in alopecia areata and establish Recommended Phase 2 Dose Provides funding needed to complete HCW9302 Phase 1 study in alopecia areata and establish Recommended Phase 2 Dose
View source ↗ - Newsglobenewswire.com·44d ago·Neutral
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors Communication with FDA at recent Type B meeting provided clear guidance for next steps to prepare IND application to support first-in-human clinical study in cancer
View source ↗ - Newsglobenewswire.com·59d ago·Neutral
…Announces Pricing of $1.5 Million Private Placement MIRAMAR, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today announced the pricing of its $1.5 million private placement (the “Offering”) with an existing stockholder of the Company, (the “Investor”).
View source ↗ - Newsglobenewswire.com·89d ago·Neutral
…constructed with novel TRBC drug development platform MIRAMAR, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associated dysplasia, together with collaborators at leading research institutions, have identified a TGF-β trap and IL-15 fusion as a novel moiety with potential app…
View source ↗ - Newsglobenewswire.com·100d ago·Neutral
…Clinical Development Highlights and Financial Results MIRAMAR, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three and six months ended June 30, 2026.
View source ↗
Earnings
Wed, Mar 31(in 4 months)
Consensus estimate $-1.39 per share
Typical surprise -220.5% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 16$-2.83 vs $-1.35miss
- Fri, Aug 14$-11.58 vs $-1.98miss
- Thu, May 14$2.22 vs $-2.64beat
- Tue, Mar 31$-15.78 vs $-5.04miss
- Fri, Nov 14$-12.12 vs $9.48miss
- Mon, Aug 18$-40.73 vs $10.80miss
Estimates and results for HCWB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HCWB officers and directors.
- Bought
- $6.3m
- Sold
- —
68 trades
0 trades
- Wong Hing Cboughtdirector, 10 percent owner, officer: Chief Executive Officer·23,210 @ $2.58·$60k·Jul 29, 2026·filing
- Flowers Leebought
- Garrett Scott Tbought
- Wong Hing Cboughtdirector, 10 percent owner, officer: Chief Executive Officer·113,879 @ $1.41·$160k·May 22, 2026·filing
- Wong Hing Cboughtdirector, 10 percent owner, officer: Chief Executive Officer·113,879 @ $1.28·$146k·May 22, 2026·filing
- Garrett Scott Tbought
- Garrett Scott Tbought
- Byam Rebeccabought
32 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in HCWB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
